稳定型冠状动脉疾病血运重建的争议。
Controversies in revascularisation for stable coronary artery disease.
机构信息
National Heart and Lung Institute, London, UK and Hammersmith Hospital, London, UK
National Heart and Lung Institute, London, UK and Hammersmith Hospital, London, UK.
出版信息
Clin Med (Lond). 2021 Mar;21(2):114-118. doi: 10.7861/clinmed.2020-0922.
Abstract
Recent randomised controlled trials, such as ISCHEMIA and ORBITA, have overturned most of what we were taught in medical school about hospital procedures considered necessary for patients with stable coronary artery disease. In this article, we discuss what these trials mean for physicians and patients considering revascularisation procedures with the hope of reducing the risk of death or alleviating angina.
摘要
最近的随机对照试验，如 ISCHEMIA 和 ORBITA，推翻了我们在医学院所学的大多数关于稳定型冠心病患者所需的医院程序的知识。在本文中，我们讨论了这些试验对考虑进行血管重建手术的医生和患者意味着什么，希望能降低死亡风险或减轻心绞痛。
相似文献
1
Controversies in revascularisation for stable coronary artery disease.稳定型冠状动脉疾病血运重建的争议。
Clin Med (Lond). 2021 Mar;21(2):114-118. doi: 10.7861/clinmed.2020-0922.
2
Optimising physiological endpoints of percutaneous coronary intervention.优化经皮冠状动脉介入治疗的生理终点。
EuroIntervention. 2021 Apr 2;16(18):e1470-e1483. doi: 10.4244/EIJ-D-20-00988.
3
Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.经皮冠状动脉介入治疗（PCI）后不完全血运重建患者应用雷诺嗪（RIVER-PCI）：一项多中心、随机、双盲、安慰剂对照试验。
Lancet. 2016 Jan 9;387(10014):136-45. doi: 10.1016/S0140-6736(15)00459-6. Epub 2015 Oct 22.
4
Impact of a comprehensive cardiac rehabilitation programme versus coronary revascularisation in patients with stable angina pectoris: study protocol for the PRO-FIT randomised controlled trial.一项针对稳定性心绞痛患者的综合心脏康复计划与冠状动脉血运重建对比的影响：PRO-FIT 随机对照试验研究方案。
BMC Cardiovasc Disord. 2023 May 5;23(1):238. doi: 10.1186/s12872-023-03266-z.
5
COURAGE, ORBITA, and ISCHEMIA: Percutaneous Coronary Intervention for Stable Coronary Artery Disease.COURAGE、ORBITA 和 ISCHEMIA 试验：稳定性冠心病的经皮冠状动脉介入治疗。
Interv Cardiol Clin. 2020 Oct;9(4):469-482. doi: 10.1016/j.iccl.2020.07.003.
6
Outcome of revascularisation in stable coronary artery disease without ischaemia: a Danish registry-based follow-up study.无缺血的稳定型冠状动脉疾病血管重建的结局：一项基于丹麦登记处的随访研究。
BMJ Open. 2017 Aug 11;7(8):e016169. doi: 10.1136/bmjopen-2017-016169.
7
Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease.血流储备分数和瞬时无波比值作为稳定型冠状动脉疾病经皮冠状动脉介入治疗安慰剂对照反应的预测指标。
Circulation. 2025 Jan 21;151(3):202-214. doi: 10.1161/CIRCULATIONAHA.124.072281. Epub 2024 Oct 27.
8
Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial.冠状动脉窦减容术治疗难治性心绞痛（ORBITA-COSMIC）：一项随机、安慰剂对照试验。
Lancet. 2024 Apr 20;403(10436):1543-1553. doi: 10.1016/S0140-6736(24)00256-3. Epub 2024 Apr 8.
9
Ischemia on Dobutamine Stress Echocardiography Predicts Efficacy of PCI: Results From the ORBITA-2 Trial.多巴酚丁胺负荷超声心动图检查显示的心肌缺血可预测经皮冠状动脉介入治疗（PCI）的疗效：ORBITA-2试验结果
J Am Coll Cardiol. 2025 May 13;85(18):1740-1753. doi: 10.1016/j.jacc.2025.02.034.
10
Percutaneous coronary revascularization versus medical therapy in chronic coronary syndromes: An updated meta-analysis of randomized controlled trials.经皮冠状动脉血运重建与慢性冠状动脉综合征药物治疗的比较：随机对照试验的更新荟萃分析。
Eur J Clin Invest. 2024 Dec;54(12):e14303. doi: 10.1111/eci.14303. Epub 2024 Aug 21.
引用本文的文献
1
Association between NT-proBNP level and the number of stents with major advanced cardiovascular events (MACE) in patients with multivessel coronary artery disease treated with percutaneous coronary intervention: A prospective cohort study.经皮冠状动脉介入治疗多支冠状动脉疾病患者 NT-proBNP 水平与支架数量及主要心血管不良事件（MACE）的关系：一项前瞻性队列研究。
Narra J. 2024 Apr;4(1):e710. doi: 10.52225/narra.v4i1.710. Epub 2024 Apr 16.
2
Remote digital smart device follow-up in prospective clinical trials: early insights from ORBITA-2, ORBITA-COSMIC, and ORBITA-STAR.前瞻性临床试验中的远程数字智能设备随访：来自ORBITA-2、ORBITA-COSMIC和ORBITA-STAR的早期见解。
Eur Heart J Suppl. 2022 Nov 11;24(Suppl H):H32-H42. doi: 10.1093/eurheartjsupp/suac058. eCollection 2022 Nov.
3
Higher Plasma Pentraxin-3 Level Predicts Adverse Clinical Outcomes in Patients With Coronary Artery Disease: A Meta-Analysis of Cohort Studies.较高的血浆五聚体-3水平可预测冠心病患者的不良临床结局：一项队列研究的荟萃分析
Front Cardiovasc Med. 2022 Jan 10;8:726289. doi: 10.3389/fcvm.2021.726289. eCollection 2021.
本文引用的文献
1
Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation.SYNTAX 评分 II 的再开发和验证：用于指导复杂冠状动脉疾病患者经皮与手术血运重建策略的个体化选择：多中心随机对照 SYNTAXES 试验的二次分析及外部队列验证。
Lancet. 2020 Oct 31;396(10260):1399-1412. doi: 10.1016/S0140-6736(20)32114-0. Epub 2020 Oct 8.
2
Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials.常规血运重建与稳定型缺血性心脏病初始药物治疗的比较：随机试验的系统评价和荟萃分析。
Circulation. 2020 Sep;142(9):841-857. doi: 10.1161/CIRCULATIONAHA.120.048194. Epub 2020 Jun 26.
3
Initial Invasive or Conservative Strategy for Stable Coronary Disease.稳定型冠心病的初始侵入性或保守治疗策略。
N Engl J Med. 2020 Apr 9;382(15):1395-1407. doi: 10.1056/NEJMoa1915922. Epub 2020 Mar 30.
4
Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials.药物洗脱支架与冠状动脉旁路移植术治疗左主干冠状动脉疾病的死亡率：随机对照试验的荟萃分析。
Eur Heart J. 2020 Sep 7;41(34):3228-3235. doi: 10.1093/eurheartj/ehaa135.
5
Effects of Percutaneous Coronary Intervention on Death and Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials.经皮冠状动脉介入治疗对稳定型和不稳定型冠状动脉疾病分层的死亡和心肌梗死的影响：一项随机对照试验的荟萃分析
Circ Cardiovasc Qual Outcomes. 2020 Feb;13(2):e006363. doi: 10.1161/CIRCOUTCOMES.119.006363. Epub 2020 Feb 17.
6
Dobutamine Stress Echocardiography Ischemia as a Predictor of the Placebo-Controlled Efficacy of Percutaneous Coronary Intervention in Stable Coronary Artery Disease: The Stress Echocardiography-Stratified Analysis of ORBITA.多巴酚丁胺负荷超声心动图缺血作为预测稳定型冠状动脉疾病经皮冠状动脉介入治疗安慰剂对照疗效的指标：ORBITA 的负荷超声心动图分层分析。
Circulation. 2019 Dec 10;140(24):1971-1980. doi: 10.1161/CIRCULATIONAHA.119.042918. Epub 2019 Nov 11.
7
Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease.左主干冠状动脉疾病经皮冠状动脉介入治疗或冠状动脉旁路移植术后 5 年的结果。
N Engl J Med. 2019 Nov 7;381(19):1820-1830. doi: 10.1056/NEJMoa1909406. Epub 2019 Sep 28.
8
Mortality From Ischemic Heart Disease.缺血性心脏病导致的死亡率
Circ Cardiovasc Qual Outcomes. 2019 Jun;12(6):e005375. doi: 10.1161/CIRCOUTCOMES.118.005375. Epub 2019 Jun 4.
9
'Ten commandments' for the 2018 ESC/EACTS Guidelines on Myocardial Revascularization.2018年欧洲心脏病学会/欧洲心胸外科学会心肌血运重建指南的“十诫”
Eur Heart J. 2019 Jan 7;40(2):79-80. doi: 10.1093/eurheartj/ehy855.
10
Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease.分数血流储备和瞬时无波比率作为稳定单支冠状动脉疾病经皮冠状动脉介入治疗安慰剂对照反应的预测因子。
Circulation. 2018 Oct 23;138(17):1780-1792. doi: 10.1161/CIRCULATIONAHA.118.033801.
Zotero 插件